STML STEMLINE THERAPEUTICS, INC WITH BUY, $36 TARGET

LADENBURG STARTS COVERAGE OF STEMLINE THERAPEUTICS (STML) WITH BUY, $36 TARGET

Font size: A | A | A

undefined undefined | S&P Marketscope

STML\
STEMLINE THERAPEUTICS, INC.

MATTHEW MORROWLADENBURG STARTS COVERAGE OF STEMLINE THERAPEUTICS (STML) WITH BUY, $36 TARGET

Analyst Matthew Kaplan tells salesforce STML is in process of developing 2 therapeutic products, SL-401, SL-701 and targeting tumor bulk, cancer stem cells, which could enable co. to generate over $500M in annual rev. Says SL-401 is being developed to treat blastic plasmacytoid dendritic cell neoplasm, acute myeloid leukemia, SL-701 for adult glioblastoma multiforme, pediatric brainstem, non-brainstem glioma. Thinks breadth of clinical programs STML has planned will attract attention of possible partners, de-risk the product portfolio as more data generated. M.Morrow|US;STML|220457494|US|54463163